Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy

July 22, 2013 updated by: SironRX Therapeutics, Inc.

A Phase I Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Needle-free Dermal Injection to Cohorts of Adults Receiving Surgical Sternotomy Incisions

This study will investigate the safety and efficacy of using JVS-100 to accelerate wound healing and reduce scar formation in subjects receiving surgical incisions ("sternotomies") during cardiovascular surgery. Twenty-five (25) subjects receiving a median sternotomy of 16 - 25 cm in the process of cardiothoracic surgery will be enrolled consecutively and be followed for 6 months post-dosing. Three cohorts of approximately 8 subjects each will be enrolled, and within each cohort subjects will be randomized 3:1 to receive a single set of needle-free dermal injections of either JVS-100 or placebo. JVS-100 or placebo will be delivered along the edge of the sternal wound using a needle-free injection device that has FDA-clearance for subcutaneous injections.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

25

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Florida
      • Tampa, Florida, United States, 33613
        • Recruiting
        • Pepin Heart Institute
        • Contact:
        • Principal Investigator:
          • Marc Bloom, MD
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern University Bluhm Cardiovascular Inst
        • Contact:
    • New York
      • New York City, New York, United States, 10467
        • Recruiting
        • Montefiore Medical Center
        • Contact:
        • Principal Investigator:
          • Robert Michler, MD
    • Ohio
      • Akron, Ohio, United States, 44304
        • Recruiting
        • Summa Health System Hospital
        • Contact:
        • Principal Investigator:
          • Eric Espinal, MD
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • Recruiting
        • University of Utah Hospital
        • Contact:
        • Principal Investigator:
          • Amit Patel, MD
    • Virginia
      • Norfolk, Virginia, United States, 23507
        • Recruiting
        • Sentara Cardiovascular Research Institute
        • Contact:
        • Principal Investigator:
          • Michael McGrath, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

38 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women 40 - 80 years of age inclusive
  • Patients undergoing median sternotomy for cardiac surgical procedures, with incision length of 16-25 cm
  • Subject must be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written informed consent
  • Subjects with BMI 25 - 40 kg/m2
  • All subjects age 50 or older must have had a Fecal occult blood test (FOBT) or fecal immunochemical test (FIT) that was negative within the last year or a colonoscopy within the last 10 years
  • Women age 40 - 65 must have had a Papanicolaou (PAP) test that was negative within the last 5 years unless a total hysterectomy has been previously performed for benign disease
  • Women age 40 or older must have had a mammogram that was negative within the last year
  • All diabetic subjects must have had an ophthalmologic exam within the last year showing no active proliferative retinopathy.

Exclusion Criteria:

  • Subject is scheduled for mechanical device assistance or, heart transplantation
  • Class IV heart failure
  • Subject had acute myocardial infarction less than 3 days prior to scheduled surgery
  • Subject is undergoing urgent bypass surgical procedure
  • History of scleroderma, a connective tissue disorder, rheumatoid arthritis, or ankylosing spondylitis or systemic lupus erythematosus (SLE)
  • Pregnant or lactating women or subjects of childbearing potential not protected by an effective method of birth control
  • Life expectancy of < 1 year
  • Diabetes mellitus with HgbA1C >10.5% tested within 2 weeks prior to surgery
  • Existing scarring in the area of study
  • Subject has received a cytotoxic agent or has a history of chest radiation therapy and/or will likely require such treatment in the 30 day period following surgery, not including use of radiation for diagnostic imaging, e.g., PET Scan, CT SCAN, Fluro, Myocardial Perfusion (SPECT).
  • Chest tattoos over the sternum, breast implants, prior mastectomies or lumpectomies
  • Subject plans to use an alternative/accessory wound healing treatment
  • Infection being treated with systemic antibiotics within 3 days of scheduled surgery
  • Chronic kidney disease (stage 5) requiring dialysis
  • Significant Hepatic disease
  • Significant is known to be infected with HBV, HIV or HCV
  • Clinically significant elevations or decreases in PT/PTT/INR/WBC
  • Concurrent medical condition that is associated with prolonged recovery from surgery (e.g., significant respiratory disease, high risk for ventilator dependence, current use of systemic steroids)
  • Subject has cognitive impairment
  • Any patient with a history of cancer with the exception of: 1) The cancer was limited to curable non-melanoma skin malignancies; 2) The cancer was removed by a successful tumor resection, with or without radiation or chemotherapy treatment, 5 years or more prior to enrollment in this study without recurrence.
  • Men unwilling to agree to barrier contraception unless previously received a vasectomy
  • Presence of any other condition that, in the opinion of the investigator, might compromise any aspect of the trial
  • Previous treatment with an angiogenic growth factor or with stem cell therapy within 1 year
  • Participation in another clinical trial of an investigational agent in the previous 30 days
  • History of drug or alcohol abuse in the past year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1
Subjects will be randomized to receive injections JVS-100 or placebo.
Biological: JVS-100 or placebo
Injections will be delivered depending on sternal incision length.
Experimental: Cohort 2
Subjects will be randomized to receive injections JVS-100 or placebo.
Biological: JVS-100 or placebo
Injections will be delivered depending on sternal incision length.
Experimental: Cohort 3
Subjects will be randomized to receive injections of JVS-100 or placebo.
Biological: JVS-100 or placebo
Injections will be delivered depending on sternal incision length.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To investigate the safety and tolerability of ascending doses of JVS-100 delivered via needle-free dermal injections to subjects receiving surgical incisions following cardiothoracic surgery.
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
To investigate the preliminary efficacy of ascending doses JVS-100 delivered via needle-free dermal injections to subjects receiving surgical incisions following cardiothoracic surgery.
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SironRX Therapeutics, Inc.

Investigators

  • Principal Investigator: Robert Michler, MD, Montefiore Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Anticipated)

December 1, 2013

Study Completion (Anticipated)

July 1, 2014

Study Registration Dates

First Submitted

August 1, 2012

First Submitted That Met QC Criteria

August 1, 2012

First Posted (Estimate)

August 3, 2012

Study Record Updates

Last Update Posted (Estimate)

July 23, 2013

Last Update Submitted That Met QC Criteria

July 22, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SRX-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Median Sternotomy

Clinical Trials on JVS-100 or placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe